Exome sequencing and digital PCR analyses reveal novel mutated genes related to the metastasis of pancreatic ductal adenocarcinoma

Cancer Biology and Therapy

Volumn 13, Issue 10, 2012, Pages 871-879

  Zhou, Bin ^a   Irwanto, Astrid ^b,c   Guo, Yun Miao ^d   Bei, Jin Xin ^d   Wu, Qiao ^a   Chen, Ge ^a   Zhang, Tai Ping ^a   Lei, Jin Jv ^d   Feng, Qi Sheng ^d   Chen, Li Zhen ^d   Liu, Jianjun ^b   Zhao, Yu Pei ^a,e  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^e INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Clonal expansion; Digital PCR; Exome capture sequencing; KRAS; Metastases; Migration; Pancreatic cancer; Proliferation; TP53

Indexed keywords

K RAS PROTEIN; PROTEIN P53;

ADULT; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CASE REPORT; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; EXOME; GENE FREQUENCY; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MALE; PANCREAS ADENOCARCINOMA; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

ALLELES; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; EXOME; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENE REGULATORY NETWORKS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE ANNOTATION; MUTATION; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS;

EID: 84864555896     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.20839     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. In CA Cancer J Clin 2010; 60:277-300 (2010 American Cancer Society, Inc., United States 2010).
2. Bayraktar S, Rocha-Lima CM. Advanced or metastatic pancreatic cancer: molecular targeted therapies. Mt Sinai J Med 2010; 77:606-19; PMID:21105124; http://dx.doi.org/10.1002/msj.20217.
3. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467:1114-7; PMID:20981102; http://dx.doi.org/10.1038/nature09515.
4. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467:1109-13; PMID:20981101; http://dx.doi.org/ 10.1038/nature09460.
5. Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SF, et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res 2007; 17:1665-74; PMID:17921354; http://dx.doi.org/10.1101/gr.6861907.
6. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321:1801-6; PMID:18772397; http://dx.doi.org/10.1126/ science.1164368.
7. Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer 1994; 58:185-91; PMID:8026879; http://dx.doi.org/10.1002/ijc.2910580207.
8. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8:27-32; PMID:7726912; http://dx.doi.org/10.1038/ng0994-27.
9. Kim DH, Crawford B, Ziegler J, Beattie MS. Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations. Fam Cancer 2009; 8:153-8; PMID:18855126; http://dx.doi.org/10.1007/s10689-008-9220-x.
10. Horii A, Nakatsuru S, Miyoshi Y, Ichii S, Nagase H, Ando H, et al. Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Res 1992; 52:6696-8; PMID:1423316.
11. Geoffroy-Perez B, Janin N, Ossian K, Laugé A, Croquette MF, Griscelli C, et al. Cancer risk in heterozygotes for ataxia-telangiectasia. Int J Cancer 2001; 93:288-93; PMID:11410879; http://dx.doi.org/10.1002/ijc.1329.
12. Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 2003; 22:395-403; PMID:12884914; http://dx.doi.org/10.1023/A:1023781114568.
13. Wolfer A, Ramaswamy S. MYC and metastasis. Cancer Res 2011; 71:2034-7; PMID:21406394; http://dx.doi.org/10.1158/0008-5472.CAN-10-3776.
14. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441:431-6; PMID:16724054; http://dx.doi.org/10.1038/nature04870.
15. Hirata H, Hinoda Y, Nakajima K, Kawamoto K, Kikuno N, Kawakami K, et al. Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways. Clin Cancer Res 2009; 15:5678-87; PMID:19755393; http://dx.doi.org/10.1158/1078-0432.CCR-09-0558.
16. Armengol G, Capellà G, Farré L, Peinado MA, MiróR, Caballín MR. Genetic evolution in the metastatic progression of human pancreatic cancer studied by CGH. Lab Invest 2001; 81:1703-7; PMID:11742040; http://dx.doi.org/10.1038/labinvest.3780383.
17. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 2010; 107:246-51; PMID:20018721; http://dx.doi.org/10.1073/pnas.0908428107.
18. Schulz P, Scholz A, Rexin A, Hauff P, Schirner M, Wiedenmann B, et al. Inducible re-expression of p16 in an orthotopic mouse model of pancreatic cancer inhibits lymphangiogenesis and lymphatic metastasis. Br J Cancer 2008; 99:110-7; PMID:18577984; http://dx.doi.org/10.1038/sj.bjc.6604457.
19. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009; 27:1806-13; PMID:19273710; http://dx.doi.org/10.1200/JCO.2008.17.7188.
20. James E, Waldron-Lynch MG, Saif MW. Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs 2009; 20:634-8; PMID:19433978; http://dx.doi.org/10.1097/CAD.0b013e32832b511e.
21. Chalasani P, Kurtin S, Dragovich T. Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation. JOP 2008; 9:305-8; PMID:18469443.
22. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011; 17:500-3; PMID:21460848; http://dx.doi.org/10.1038/nm. 2344.
23. Strimpakos AS, Syrigos KN, Saif MW. The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut Liver 2010; 4:433-49; PMID:21253292; http://dx.doi.org/10.5009/gnl.2010.4.4.433.
24. Jones SJ, Laskin J, Li YY, Griffith OL, An J, Bilenky M, et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol 2010; 11:82; PMID:20696054; http://dx.doi.org/10.1186/gb-2010-11-8- r82.
25. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25:1754-60; PMID:19451168; http://dx.doi.org/10.1093/bioinformatics/btp324.
26. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol 2011; 29:24-6; PMID:21221095; http://dx.doi.org/10.1038/nbt.1754.
27. Goya R, Sun MG, Morin RD, Leung G, Ha G, Wiegand KC, et al. SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics 2010; 26:730-6; PMID:20130035; http://dx.doi.org/10.1093/ bioinformatics/btq040.
28. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461:809-13; PMID:19812674; http://dx.doi.org/10.1038/ nature08489.
29. Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 1975; 15:741-7; PMID:1140870; http://dx.doi.org/10.1002/ ijc.2910150505.
30. Okabe T, Yamaguchi N, Ohsawa N. Establishment and characterization of a carcinoembryonic antigen (CEA)-producing cell line from a human carcinoma of the exocrine pancreas. Cancer 1983; 51:662-8; PMID:6821838; http://dx.doi.org/10. 1002/1097-0142(19830215)51:4〈662::AID-CNCR2820510419〉3.0.CO;2-X.
31. Chen WH, Horoszewicz JS, Leong SS, Shimano T, Penetrante R, Sanders WH, et al. Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. In Vitro 1982; 18:24-34; PMID:7182348; http://dx.doi.org/10.1007/BF02796382.
32. Tan MH, Nowak NJ, Loor R, Ochi H, Sandberg AA, Lopez C, et al. Characterization of a new primary human pancreatic tumor line. Cancer Invest 1986; 4:15-23; PMID:3754176; http://dx.doi.org/10.3109/07357908609039823.
33. Kyriazis AP, McCombs WB, 3rd, Sandberg AA, Kyriazis AA, Sloane NH, Lepera R. Establishment and characterization of human pancreatic adenocarcinoma cell line SW-1990 in tissue culture and the nude mouse. Cancer Res 1983; 43:4393-401; PMID:6871872.